Trial Profile
Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2018
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 31 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Feb 2010 New trial record